- Home
- CRMD
CRMD
CorMedix Inc.
as 02-21-2025 4:00pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 645.0M | IPO Year: | 2010 |
| Target Price: | $15.67 | AVG Volume (30 days): | 891.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $13.85 | Next Earning Date: | 03-11-2025 |
| Revenue: | $12,262,234 | Revenue Growth: | 41184.20% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 234.92% |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
GlobeNewswire
a month ago
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities
GlobeNewswire
a month ago
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update
TipRanks
2 months ago
CorMedix price target raised to $12 from $11 at RBC Capital
GlobeNewswire
2 months ago
CorMedix Inc. Added to Nasdaq Biotechnology Index
GlobeNewswire
3 months ago
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products
GlobeNewswire
4 months ago
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
Simply Wall St.
4 months ago
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic
Compare CRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.